RGI
NVCR icon

River Global Investors’s NovoCure NVCR Stock Holding History

River Global Investors’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-89,451
Closed -$1.78M – 114
2017
Q3 		$1.78M Sell
89,451
-38,069
-30% -$748K 0.26% 95
2017
Q2 		$2.2M Buy
127,520
+11,500
+10% +$148K 0.41% 81
2017
Q1 		$937K Buy
+116,020
New +$838K 0.21% 95

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

River Global Investors's NVCR Position: Q4 2017 in Review

River Global Investors sold out of NovoCure (NVCR) in Q4 2017, closing a stake of 89,451 shares — an estimated $1.78M sold.

River Global Investors first reported a position in NVCR in Q1 2017 and held it in 3 quarters. The position peaked at $2.2M in Q2 2017. 128 funds tracked by Wall St. Rank hold NVCR as of Q4 2017.

  • River Global Investors reported no remaining NovoCure position as of Q4 2017 after selling out during the quarter.
  • River Global Investors sold 89,451 NovoCure shares in Q4 2017, an estimated $1.78M.
  • River Global Investors first reported a position in NovoCure in Q1 2017 and held it in 3 quarters.
  • River Global Investors's NovoCure position peaked at $2.2M in Q2 2017.
  • 128 funds tracked by Wall St. Rank held NovoCure as of Q4 2017.

Based on River Global Investors's 13F filing for Q4 2017, filed 7 Feb 2018.